CJC-1295

Overview

CJC-1295 is a modified version of the first 29 amino acids of growth hormone-releasing hormone, the signal the brain uses to tell the pituitary gland to release growth hormone. The changes make it more stable. The "DAC" version adds a chemical group that lets it bind to blood proteins and last for days. The "no DAC" version, often called modified GRF (1-29), acts for a much shorter time.

What the research has looked at

A small human study in healthy adults found that the DAC form raised growth hormone and IGF-1 levels for an extended period. Research has focused on these hormone measurements rather than on health outcomes.

What we do not know

• Raising hormone levels is not the same as proven benefit, and no large trials have tested clinical outcomes.
• Long-term effects of sustained growth hormone stimulation are not established.
• It is frequently sold in blends, and those blends have not been studied as combinations.

Regulatory context

CJC-1295 is not an approved medicine, and it is prohibited in sport.

Related pages

See also Ipamorelin, Sermorelin and Tesamorelin.

References & further reading

• Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

Search PubMed for CJC-1295